Novel immunotherapeutic approaches to the treatment of urothelial carcinoma
Immunotherapy has long played a role in urothelial cancers with the use of bacille Calmette Guérin (BCG) being a mainstay in the treatment of nonmuscle invasive bladder cancer. Novel therapeutic approaches have not significantly impacted mortality in this population and so a renaissance in immunotherapy has resulted. This includes recombinant BCG, oncolytic viruses, monoclonal antibodies, vaccines, and adoptive T-cell therapy. Herein, we provide a review of the current state of the art and future therapies regarding immunotherapeutic strategies for urothelial carcinoma.
Source: Therapeutic Advances in Urology - Category: Urology & Nephrology Authors: Muthigi, A., George, A. K., Brancato, S. J., Agarwal, P. K. Tags: Reviews Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Immunotherapy | Urology & Nephrology | Vaccines